Chargement en cours...
Anti-tumour necrosis factor therapy enhances mucosal healing through down-regulation of interleukin-21 expression and T helper type 17 cell infiltration in Crohn's disease
Anti-tumour necrosis factor (TNF) monoclonal antibody (mAb) (infliximab, IFX) has been shown to be highly effective in the management of Crohn's disease (CD). Herein we investigated the potential role of IFX in inducing clinical remission and regulating interleukin (IL)-21 expression and T help...
Enregistré dans:
| Auteurs principaux: | , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Blackwell Science Inc
2013
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3694540/ https://ncbi.nlm.nih.gov/pubmed/23607532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cei.12084 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|